Early Phase I Data for Sirna s AMD Drug Positive; Phase II Planned for Mid-2006

FORT LAUDERDALE, Fla. -- Sirna Therapeutics released this week the first ever clinical data for an RNAi-based drug, announcing interim results from an ongoing phase I study of the company s age-related macular degeneration treatment Sirna-027. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.